Cyclerion Therapeutics Inc
NASDAQ:CYCN

Watchlist Manager
Cyclerion Therapeutics Inc Logo
Cyclerion Therapeutics Inc
NASDAQ:CYCN
Watchlist
Price: 1.54 USD 11.59% Market Closed
Market Cap: $6.1m

Operating Margin

-127.3%
Current
Improving
by 1 939.4%
vs 3-y average of -2 066.6%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-127.3%
=
Operating Income
$-3.6m
/
Revenue
$2.9m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-127.3%
=
Operating Income
$-3.6m
/
Revenue
$2.9m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Cyclerion Therapeutics Inc
NASDAQ:CYCN
5.7m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
185.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
168.8B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.2B USD
Loading...

Market Distribution

Lower than 86% of companies in the United States of America
Percentile
14th
Based on 14 112 companies
14th percentile
-127.3%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Cyclerion Therapeutics Inc
Glance View

Market Cap
6.1m USD
Industry
Biotechnology

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for serious and orphan diseases, through the use of soluble guanylate cyclase (sGC) pharmacology. The company is headquartered in Boston, Massachusetts and currently employs 32 full-time employees. The company went IPO on 2019-03-18. The firm's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. Its CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with CSF-to-plasma exposure relative to CY6463. CY3018 is focused on sGC stimulation for the treatment of disorders of the CNS. Its non-CNS assets include Praliciguat and Olinciguat. Praliciguat is an orally administered, once-daily systemic sGC stimulator. Olinciguat is an orally administered, once-daily, vascular sGC stimulator.

CYCN Intrinsic Value
4.78 USD
Undervaluation 68%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-127.3%
=
Operating Income
$-3.6m
/
Revenue
$2.9m
What is Cyclerion Therapeutics Inc's current Operating Margin?

The current Operating Margin for Cyclerion Therapeutics Inc is -127.3%, which is above its 3-year median of -2 066.6%.

How has Operating Margin changed over time?

Over the last 3 years, Cyclerion Therapeutics Inc’s Operating Margin has increased from -3 422.9% to -127.3%. During this period, it reached a low of -7 745% on Mar 31, 2023 and a high of -127.3% on Oct 30, 2025.

Back to Top